Whitehawk Therapeutics (WHWK) Change in Accured Expenses (2010 - 2026)

Whitehawk Therapeutics (WHWK) has reported Change in Accured Expenses for 17 consecutive years, with -$3.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 458.36% year-over-year to -$3.5 million; the TTM figure through Mar 2026 stood at -$4.7 million (down 129.65% YoY), while the FY2025 annual figure was -$202000.0, up 97.93% from the prior year.
• Change in Accured Expenses eased to -$3.5 million in Q1 2026 per WHWK's latest filing, from -$1.2 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $5.0 million in Q3 2022 and bottomed at -$10.2 million in Q4 2024.
• Historically, Change in Accured Expenses has averaged -$683266.7 across 5 years, with a median of $975000.0 in 2025.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses plunged 797.47% — and 2023, when it jumped 279.66%.
• Whitehawk Therapeutics' Change in Accured Expenses stood at $1.3 million in 2022, then surged by 279.66% to $4.9 million in 2023, then sank by 305.52% to -$10.2 million in 2024, then soared by 88.42% to -$1.2 million in 2025, then plunged by 196.86% to -$3.5 million in 2026.
• Business Quant data shows WHWK's Change in Accured Expenses at -$3.5 million in Q1 2026, -$1.2 million in Q2 2025, and $975000.0 in Q1 2025.